Stockscreener 앱 받기
18.00
2.22%
-0.4091
전일 마감가:
$18.41
열려 있는:
$18.68
하루 거래량:
30,040
Relative Volume:
0.53
시가총액:
$32.82M
수익:
-
순이익/손실:
$-4.85M
주가수익비율:
-58.07
EPS:
-0.31
순현금흐름:
$-3.95M
1주 성능:
-9.50%
1개월 성능:
-5.16%
6개월 성능:
+146.25%
1년 성능:
+78.05%
1일 변동 폭
$18.00
$19.35
1주일 범위
$18.00
$22.90
52주 변동 폭
$5.40
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
명칭
Cadrenal Therapeutics Inc
전화
904-300-0701
주소
822 A1A NORTH, PONTE VEDRA
CVKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
18.00 | 32.82M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.14 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
695.32 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.62 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.12 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.49 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-18 | 개시 | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
CVKD stock hits 52-week high at $20.79 amid robust growth By Investing.com - Investing.com South Africa
CVKD stock hits 52-week high at $20.79 amid robust growth - Investing.com India
(CVKD) Trading Signals - Stock Traders Daily
(CVKD) Trading Advice - Stock Traders Daily
Cadrenal Therapeutics Announces New Chief Medical Officer in Recent SEC Filing - Defense World
Biondi becomes managing partner at Flagship - BioCentury
Cadrenal Therapeutics Appoints New Chief Medical Officer - TipRanks
Clinical Trials News Live Feed - StockTitan
Cadrenal Therapeutics appoints new chief medical officer - MSN
Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire
Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - StockTitan
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace
Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan
(CVKD) Investment Report - Stock Traders Daily
Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World
Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals
Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily
Ponte Vedra biotech firm opens the Nasdaq - The Business Journals
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire
AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 11.6% – Time to Buy? - Defense World
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online
CVKDCadrenal Therape Latest Stock News & Market Updates - StockTitan
Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire
Cadrenal Therapeutics to Showcase Novel Anticoagulant Tecarfarin at J.P. Morgan Healthcare Conference - StockTitan
(CVKD) Trading Report - Stock Traders Daily
What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World
CVKD: Recent Financings Raise $9.8 Million… - MSN
Kairos Pharma approved to dual list on Upstream - MSN
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - StockTitan
(CVKD) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com
Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data | CVKD Stock News - StockTitan
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS - PR Newswire
Cadrenal shares gain; analyst highlights Buy rating and key LVAD trial advancements - Investing.com Canada
Cadrenal Therapeutics Provides Third-Quarter Corporate Update - Defense World
Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks
Cadrenal Therapeutics Raises $9.8M, Advances Unique Anticoagulant Drug Development | CVKD Stock News - StockTitan
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance
(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com
Cadrenal Therapeutics Inc (CVKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.64%
0.75%
자본화:
|
볼륨(24시간):